Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frédéric Millot,
Joëlle Guilhot,
Meinolf Suttorp,
Adalet Meral Güneş,
Petr Sedlacek,
Eveline De Bont,
Chi Kong Li,
Krzysztof Kalwak,
Birgitte Lausen,
Srdjana Culic,
Michael Dworzak,
Emilia Kaiserova,
Barbara De Moerloose,
Farah Roula,
Andrea Biondi,
André Baruchel
Affiliations
Frédéric Millot
Inserm CIC 1402, University Hospital, Poitiers, France
Joëlle Guilhot
Inserm CIC 1402, University Hospital, Poitiers, France
Meinolf Suttorp
Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany
Adalet Meral Güneş
Department of Pediatric Hematology, Uludağ University Hospital, Görükle Bursa, Turkey
Petr Sedlacek
Department of Pediatric Hematology–Oncology, University Hospital Motol, Charles University, Prague, Czech Republic
Eveline De Bont
Department of Pediatric Oncology/Hematology, University Medical Center Groningen, University of Groningen, the Netherlands, and Dutch Childhood Oncology Group, the Hague, the Netherlands
Chi Kong Li
Department of Pediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, China
Krzysztof Kalwak
Department of Pediatric Hematology Oncology and Transplantation, Wroclaw Medical University, Poland
Birgitte Lausen
Department of Pediatrics, Rigshospitalet, University Hospital, Copenhagen, Denmark
Srdjana Culic
Department of Pediatric Hematology Oncology Immunology and Medical Genetics, Clinical Hospital Split, Croatia
Michael Dworzak
Children’s Cancer Research Institute and St. Anna Children’s Hospital, Vienna, Austria
Emilia Kaiserova
Department of Pediatric Oncology of University Children’s Hospital, Bratislava, Slovakia
Barbara De Moerloose
Department of Pediatrics, Ghent University Hospital, Belgium
Farah Roula
Department of Pediatrics, Saint George Hospital University Medical Center, Beirut, Lebanon
Andrea Biondi
Department of Pediatrics, University of Milano-Bicocca, San Gerardo Hospital, Fondazione MBBM, Monza, Italy
André Baruchel
Department of Pediatric Hematology, Robert Debré Hospital, Paris, France
The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%–94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%–99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%–98%), 88% (95% CI: 76%–95%) and 67% (95% CI: 48%–81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P
